LILRB4 and Miyoshi myopathy: A potential novel target for targeted therapy in MM is immunoglobulin-like transcript 3 (ILT3), which is an immunoreceptor tyrosine-based inhibition motif-containing receptor, with high expression on MM cells and low or absent expression in normal tissues [73].